Skip to main content

Table 1 Predictive factors for survival and recurrence

From: Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma

 

Overall Survival

Progression-free Survival

Covariates

P value logrank

P value cox

HR, 95%CI cox

P value logrank

P value cox

HR, 95%CI cox

Age at PM

 ≥18 (n = 26)

0.615

0.620

1.279, 0.483–3.387

0.208

0.228

0.604, 0.267–1.37

 < 18 (n = 12)

Gender

 Male (n = 27)

0.671

0.675

0.81, 0.303–2.167

0.753

0.761

0.884, 0.399–1.958

 Female (n = 11)

Timing

 Synchronous (n = 12)

0.381

0.390

1.544, 0.574–4.153

0.123

0.14

1.859, 0.817–4.232

 Metachronous (n = 25)

Progression under CHT

 No (n = 12)

0.003

0.011

0.129, 0.027–0.622

0.050

0.071

0.404, 0.15–1.082

 Yes (n = 10)

Surgical approach

 Thoracotomy (n = 36)

0.272

0.478

22.451, 0.004–122,339.634

0.524

0.546

1.853, 0.251–13.692

 VATS (n = 2)

Metastases size

 > 15 mm (n = 14)

0.339

0.351

0.627, 0.235–1.674

0.725

0.734

1.145, 0.524–2.505

 ≤15 (n = 20)

LN resected

 Yes (n = 20)

0.134

0.148

0.472, 0.171–1.306

0.104

0.121

0.536, 0.244–1.178

 No (n = 16)

LN positive

 Yes (n = 1)

< 0.001

N/A

N/A

0.072

0.130

0.174, 0.018–1.673

 No (n = 19)

G

 2,3 (n = 36)

0.6

0.606

1.474, 0.336–6.471

0.952

0.954

0.958, 0.226–4.059

 1 (n = 2)

N° of Metastases

 ≤3 (n = 20)

0.002

0.005

0.242, 0.089–0.64

0.001

0.003

0.291, 0.130–0.651

 > 3 (n = 16)

Repeat PM

 Yes (n = 19)

0.573

0.579

0.766, 0.3–1.961

0.226

0.246

0.636, 0.297–1.366

 No (n = 19)

Unilateral/Bilateral PM

 Unilateral (n = 19)

0.517

0.523

0.744, 0.3–1.842

0.434

0.451

0.753, 0.36–1.573

 Bilateral (n = 19)

Histology (CS = 5, OST = 20, ES = 13)

0.184

0.824

1.09, 0.513–2.315

0.428

0.845

1.061, 0.587–1.915

  1. G Tumor grade, R Completeness of resection, LN Lymph node, PM Pulmonary metastasectomy, CS Chrondrosarcoma, OST Osteosarcoma, ES Ewing’s sarcoma